Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
Drug Metabolism and Personalized Therapy
ISSN 2363-8907 · eISSN 2363-8915 · Walter de Gruyter
Drug Metabolism and Personalized Therapy: subscription journal; APC about USD 2,712; median 82 days to acceptance (46 articles, last 24 months); 28 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Drug Metabolism and Personalized Therapy is published by Walter de Gruyter. By OpenAlex counts of its recent articles, its largest topics are Pharmacogenetics and Drug Metabolism, Genetic Associations and Epidemiology and Nutrition, Genetics, and Disease, together about 54.4% of its articles. Its main subfields are Pharmacology. (generated from OpenAlex topic counts and CAS ranking data)
About this journal The current volume of Drug Metabolism and Personalized Therapy (DMPT) is open access via Subscribe to Open (S2O). All accepted articles will be published under a Creative Commons license at no cost to authors. Learn more about De Gruyter Brill’s Subscribe to Open program.ObjectiveDrug Metabolism and Personalized Therapy (DMPT) offers up-to-date research articles, reviews and opinion papers from the broad field of personalized therapy and pharmacogenomics. Specifically, it covers the following fields: pharmacogenetics, pharmacogenomics and drug metabolism research, dealing with established, new and potential drugs, herbal medicinal products, environmentally toxic chemicals, the mechanisms by which drugs and herbsc an interact with each other and with biological systems, and the pharmacological and toxicological consequencesof these interactions, as well as drug metabolism and excretion. More generally, it is concerned with the area of therapeutic individualization, particularly on the basis of pharmacogenetics, with regards to the use of pharmaceuticals and herbal medicine, including traditional medicine.DMPT is an online only journal that is published quarterly. All contributions submitted for publication in DMPT are subject to single-anonymized peer review by at least two experts in the field, selected and invited by the Editor-in-Chief and a dedicated Editorial Team. DMPT only publishes articles in English.Please submit your manuscript hereTopicsdrug metabolizing enzymes //pharmacogenetics and pharmacogenomics // biochemical pharmacology // molecular pathology // clinical phar macology // pharmacokinetics and drug-drug interactions // immunopharmacology // neuropsychopharmacology // herbal medicine and traditional medicineArticle formatsResearch Articles, Reviews and Mini Reviews, Opinion Papers, Short Communications, Letters to the Editor, Case Reports, EditorialsUseful links Instructions for AuthorsSubmission ChecklistTemplate for Ethical and Legal DeclarationsManuscript Preparation and Manuscript TemplatesResources for AuthorsLicense to PublishAuthor Language ServiceData Sharing PolicyRights and Permissions Your Benefits Specialized, comprehensive and cutting-edge approach to drug metabolism researchState-of-the-art research resultsHigh quality peer-reviewInternational readership and global reachEach article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing servicesSecure arch
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
Editor-in-chief Adrián LlerenaPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics32.8%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology12.9%
- Nutrition, Genetics, and DiseaseBiochemistry, Genetics and Molecular Biology8.7%
- Drug Transport and Resistance MechanismsMedicine6%
- Medicinal Plant ResearchAgricultural and Biological Sciences3.9%
- Phytochemicals and Medicinal PlantsMedicine2.9%
- Forensic Toxicology and Drug AnalysisPharmacology, Toxicology and Pharmaceutics2.7%
- Complementary and Alternative Medicine StudiesMedicine2.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| General Pharmacology, Toxicology and Pharmaceutics | Q2 | 30/79 | 62nd |
| Pharmacology (medical) | Q3 | 158/278 | 43rd |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
CASPublisher website
Other: EBSCO, ProQuest, Baidu, OCLC
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 3.2LetPub ·
- CiteScore (publisher)
- 3.2Publisher website ·
- SJR 2026-06
- 0.32LetPub ·
- SNIP 2026-06
- 0.45LetPub ·
- h-index
- 22OpenAlex ·
- i10-index
- 89OpenAlex ·
- 2-year mean citedness
- 2.2OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 450 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 26 | 23 | 256 |
| 2025 | 28 | 3 | 439 |
| 2024 | 33 | 5 | 425 |
| 2023 | 36 | 12 | 465 |
| 2022 | 42 | 10 | 391 |
| 2021 | 77 | 5 | 333 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
82 daysMedian, submission to acceptance · P25–P75 66 days – 119 days
- Acceptance to online
- median 45 days (46 articles)
- Submission to online
- median 124 days
- Sample
- 46 articles with submission and acceptance dates (56 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | EUR 2,400 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Walter de Gruyter
- ISSN
- 2363-8907
- Electronic ISSN
- 2363-8915
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Drug Metabolism and Personalized Therapy
How long does peer review take at Drug Metabolism and Personalized Therapy?
Based on the dates recorded on 46 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 82 days (interquartile range 66–119 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Drug Metabolism and Personalized Therapy?
According to LetPub and DOAJ records, Drug Metabolism and Personalized Therapy is indexed in Scopus. The journal's website also lists CAS; that list has not been checked against each database.
Is Drug Metabolism and Personalized Therapy open access, and what is the APC?
Drug Metabolism and Personalized Therapy is a subscription journal. APC about USD 2,712.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .